AusperBio Gains NMPA Approval for Phase III Trials of AHB-137 in Chronic Hepatitis B
Sino-US liver therapy developer AusperBio announced that the National Medical Products Administration (NMPA) has approved...
Clinical trial approval / initiation
Simcere Zaiming Receives FDA Clearance for Phase I Trial of FGFR2b-Targeting ADC SIM0686
China-based Simcere Pharma’s (HKG: 2096) oncology arm, Simcere Zaiming Pharmaceutical, has secured U.S. FDA clearance...
Bio-Thera’s BAT4406F Gets NMPA Nod for MCD and FSGS Clinical Trials
Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that its investigational drug, BAT4406F injection, has received approval...
Huadong Medicine Receives NMPA Approval for HDM2012 Clinical Trials in Advanced Solid Tumors
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...
Youcare Pharma Subsidiary Gains NMPA Clearance for Phase I Study of siRNA Hypertension Drug YKYY029
China-based Youcare Pharma (SHA: 688658) announced that its subsidiary Youcare InnoTech and partner Hangzhou Tianlong...
CanSino Bio Receives NMPA Approval for Phase I/II Trial of Recombinant Polio Vaccine
China-based CanSino Biologics Inc., (HKG: 6185) announced that it and its subsidiary CanSino (Shanghai) Biotechnology...
Hengrui Pharmaceuticals’ SHR-8068 Gains NMPA Approval for NSCLC and Colorectal Cancer Trials
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical...
Fosun Pharma’s Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its Zhejiang Xinghao...
Haisco Pharma Receives FDA Approval for Clinical Trials of Autoimmune Drug HSK47388
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial...
Huadong Medicine Receives FDA Approval for Clinical Trials of Innovative ADC HDM2020
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...
Peijia Medical Completes First Patient Implantation for MonarQ TTVR System in Global Clinical Study
China-based Peijia Medical Ltd (HKG: 9996) announced the successful completion of the first patient implantation...
Merck Initiates EXPrESSIVE Phase III Trial for Once-Monthly HIV PrEP Drug MK-8527
Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) announced the initiation of the EXPrESSIVE Phase...
China Medical System’s CMS-D001 Gains NMPA Approval for Atopic Dermatitis Trials
China Medical System Holdings Limited (CMS; HKG: 0867) announced that it has received clinical trial...
Shanghai Henlius Biotech Initiates US Patient Dosing in Phase III Trial for HER2-Positive Gastric Cancer
China-based Shanghai Henlius Biotech Inc., (HKG: 2696) announced the first patient dosing in the US...
Sichuan Biokin’s Iza-bren Approved for Phase II Clinical Study in Renal Cell Carcinoma
China’s Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical...
YolTech Therapeutics Receives NMPA Clearance for YOLT-101 in HeFH Clinical Study
Shanghai-based YolTech Therapeutics announced that it has received clearance from the National Medical Products Administration...
InnoCare Pharma Receives FDA Approval for Mesutoclax in Myeloid Malignancies
Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical trial...
Jiangsu Jibeier Receives NMPA Approval for Clinical Trials of JJH201601 Liposome in Advanced HNSCC
China-based Jiangsu Jibeier Pharm Co., Ltd (SHA: 688566) announced that it has received clinical approval...
Fosun Pharmaceutical Launches Phase III Study for Fumaining in Pediatric Low-Grade Glioma
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced the initiation of a...
Zhimeng Biopharma’s CB03-154 Receives CDE Approval for ALS Phase II/III Clinical Study
China-based Shanghai Zhimeng Biopharma, Inc. is set to carry out a Phase II/III clinical study...